A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of GCC19CART for Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Latest Information Update: 24 Sep 2024
Price :
$35 *
At a glance
- Drugs ICTCAR CRC (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Acronyms CARAPIA-1
- Sponsors Innovative Cellular Therapeutics
- 19 Sep 2024 Results published in the Innovative Cellular Therapeutics Media Release.
- 04 Jun 2024 Results (n=5) presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 10 Apr 2024 Results (at data cut off 1 Nov 2023, n=4) assessing safety and efficacy of GCC19CART, for patients with metastatic colorectal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research